Fish oil in chronic psychiatric outpatients with anxiety and mood disorders.

Adjunctive natural low dose docosahexaenoic acid (DHA) omega-3 in a 16 week random double-blind placebo controlled (RDBPC) cross-over withdrawal study in a group of chronic, psychiatric out-patients with anxiety and mood disorders.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000390684

Enrollment

Registered

2014-04-10

Start date

2014-05-01

Completion date

2016-02-05

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To investigate the effectiveness of the adjunctive role of DHA omega-3 in outpatients with chronic anxiety and depression.

Interventions

Natural low dose docosahexaenoic acid (DHA) omega-3 (NeuroSpark) 130-390mg per day in addition to standard psychiatric treatments. The dose in the study is the dose which has been found clinically to be appropriate and efficacious for each individual entering the study. Oral. This study medication will be administered for 16 weeks (24 week study minus 8 weeks on placebo = 16 weeks of study medication). There is no washout period. Adherence to study medication regimen will be monitored

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Outpatients with chronic anxiety and/or depressive symptoms. 2. Patients currently taking DHA (NeuroSpark) capsules for at least 3 months prior to study entry.

Exclusion criteria

1. ADHD 2. Brain injury 3. Mild cognitive impairment 4. Dementias 5. Substance dependence and/or abuse 6. Schizophrenia 7. Acutely suicidal patients 8. Chronic unstable medical conditions

Outcome results